Tag:
Apotex
Latest Headlines
Latest Headlines
Generic floodgates open for Plavix in U.S.
Plavix is a blood thinner from Bristol-Myers Squibb ($BMY). Generic Plavix is a Bristol-Myers profits thinner that is going to be produced by just about everybody and their brother.
UPDATED: Supreme Court upholds Unigene's nasal delivery patent
Unigene Laboratories can hold on to its patent for Fortical, after the Supreme Court denied Apotex's petition this week.
UPDATED: Apotex recalls BP med over empty capsules
Bad news coming out of Canada for Apotex. Canadian regulators are informing hypertensive patients the drugmaker is conducting a voluntary recall of one lot of Apo-Ramipril 5-mg capsules.
Apotex says FDA import ban, delays 'decimated' its business
Apotex claims in a filing that the FDA "decimated" its business by issuing an import ban against drugs made at two of its Canadian facilities.
Sanofi, BMS collect their $444M in Plavix damages
Apotex has finally paid its Plavix dues. The generics maker has handed over $444 million to Sanofi ( $SNY ) and Bristol-Myers Squibb ( $BMY ), as repayment for its premature launch of generic Plavix back...
Court upholds $442M Plavix judgment against Apotex
Bristol-Myers Squibb ( $BMY ) and Sanofi ( $SNY ) may finally get their money from Plavix copycat Apotex--but it won't be as much as the two companies wanted. A U.S. appeals panel upheld a trial court's
GSK partner holds off generic rival for Lovaza
GlaxoSmithKline and its Lovaza partner may escape generic competition on the drug until 2015. Pronova BioPharma, which makes the fish-oil-derived treatment, inked a deal with Apotex that allows the
Sanofi, BMS win $442M in damages from Apotex
Generics makers, be warned: Premature copycat launches really are risky. That's the message in a new, $442.2 million court ruling against Apotex. A Manhattan judge ordered the generics company to pay
Apotex petitions SCOTUS for Cozaar/Hyzaar exclusivity review
The voice of Michael Corleone--"Just when I thought I was out...they pull me back in"--played over and over again in our heads today when we learned that Apotex filed a Petition for Writ of
Bisaro advised by judge to testify in FTC probe
A federal judge has recommended that Watson Pharmaceuticals ( NYSE: WPI ) CEO Paul Bisaro be forced to testify in a Federal Trade Commission probe of a patent settlement between the generic drugmaker
